18F-Fluoroestradiol (FES) and18F-Fluorodeoxyglucose (FDG) PET imaging in male breast cancer

Conclusions: FES and FDG uptake in multiple lesions from ER+ male breast cancer patients did not differ from female breast cancer. Response and survival are also similar in male and female breast cancer patients in our study. Male breast cancer patients are appropriate for inclusion in imaging and clinical trials of endocrine and molecularly targeted therapies which are synergistic with endocrine therapy. Research Support: P01CA42045, R01CA72064, R01CA148131, DOD W81XWH-04-01-0675

Source: Journal of Nuclear Medicine - May 23, 2018 Category: Nuclear Medicine Authors: Peterson, L., Manohar, P., Wu, V., Jenkins, I., Novakova, A., Specht, J., Mankoff, D., Linden, H. Tags: First-in-Human & amp; New Human Applications Source Type: research